CVE:EMC

Emblem Competitors

$1.88
+0.03 (+1.62 %)
(As of 03/18/2019)
Add
Compare
Today's Range
$1.84
Now: $1.88
$1.88
50-Day Range
$1.88
MA: $1.88
$1.88
52-Week Range
$0.83
Now: $1.88
$2.12
Volume597,714 shs
Average Volume865,800 shs
Market Capitalization$245.45 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Emblem (CVE:EMC) Vs. WEED, LEAF, OGI, ICC, CMED, and MJN

Should you be buying EMC stock or one of its competitors? Companies in the sub-industry of "cannabis" are considered alternatives and competitors to Emblem, including Canopy Growth (WEED), Leaf Mobile (LEAF), OrganiGram (OGI), ICC Labs (ICC), (CMED.TO) (CMED), and (MJN.V) (MJN).

Canopy Growth (TSE:WEED) and Emblem (CVE:EMC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Canopy Growth and Emblem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth44001.50
Emblem0000N/A

Canopy Growth currently has a consensus price target of C$38.46, indicating a potential upside of 18.49%. Given Canopy Growth's higher possible upside, analysts plainly believe Canopy Growth is more favorable than Emblem.

Profitability

This table compares Canopy Growth and Emblem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy GrowthN/AN/AN/A
EmblemN/AN/AN/A

Earnings and Valuation

This table compares Canopy Growth and Emblem's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy GrowthC$506.12 million24.54$-2,459,879,050.00C($6.43)-5.05
Emblem$5.71 million43.02$-24,806,020.00($0.19)-9.89

Emblem has lower revenue, but higher earnings than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Leaf Mobile (TSE:LEAF) and Emblem (CVE:EMC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Leaf Mobile and Emblem, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Leaf Mobile00103.00
Emblem0000N/A

Leaf Mobile currently has a consensus target price of C$0.75, indicating a potential upside of 111.27%. Given Leaf Mobile's higher probable upside, research analysts clearly believe Leaf Mobile is more favorable than Emblem.

Profitability

This table compares Leaf Mobile and Emblem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Leaf MobileN/AN/AN/A
EmblemN/AN/AN/A

Valuation & Earnings

This table compares Leaf Mobile and Emblem's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Leaf MobileC$19.24 million14.11$-4,586,262.00C($0.01)-59.17
Emblem$5.71 million43.02$-24,806,020.00($0.19)-9.89

Leaf Mobile has higher revenue and earnings than Emblem. Leaf Mobile is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Summary

Leaf Mobile beats Emblem on 5 of the 7 factors compared between the two stocks.

OrganiGram (TSE:OGI) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for OrganiGram and Emblem, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram42201.75
Emblem0000N/A

OrganiGram presently has a consensus price target of C$3.77, indicating a potential upside of 26.44%. Given OrganiGram's higher possible upside, research analysts clearly believe OrganiGram is more favorable than Emblem.

Profitability

This table compares OrganiGram and Emblem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGramN/AN/AN/A
EmblemN/AN/AN/A

Valuation and Earnings

This table compares OrganiGram and Emblem's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGramC$72.40 million12.32$-340,283,853.00C($1.14)-2.62
Emblem$5.71 million43.02$-24,806,020.00($0.19)-9.89

Emblem has lower revenue, but higher earnings than OrganiGram. Emblem is trading at a lower price-to-earnings ratio than OrganiGram, indicating that it is currently the more affordable of the two stocks.

Summary

OrganiGram beats Emblem on 4 of the 7 factors compared between the two stocks.

ICC Labs (CVE:ICC) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Earnings & Valuation

This table compares ICC Labs and Emblem's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICC LabsC$533,684.00419.04$2.35 millionC$0.0295.29
Emblem$5.71 million43.02$-24,806,020.00($0.19)-9.89

ICC Labs has higher earnings, but lower revenue than Emblem. Emblem is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ICC Labs and Emblem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICC LabsN/AN/AN/A
EmblemN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for ICC Labs and Emblem, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICC Labs0000N/A
Emblem0000N/A

Summary

ICC Labs beats Emblem on 4 of the 5 factors compared between the two stocks.

Emblem (CVE:EMC) and (CMED.TO) (TSE:CMED) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Valuation and Earnings

This table compares Emblem and (CMED.TO)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71 million43.02C$-24,806,020.00($0.19)-9.89
(CMED.TO)N/AN/AN/AN/AN/A

(CMED.TO) has lower revenue, but higher earnings than Emblem.

Profitability

This table compares Emblem and (CMED.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmblemN/AN/AN/A
(CMED.TO)N/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Emblem and (CMED.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emblem0000N/A
(CMED.TO)0000N/A

Summary

Emblem beats (CMED.TO) on 1 of the 1 factors compared between the two stocks.

Emblem (CVE:EMC) and (MJN.V) (CVE:MJN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Emblem and (MJN.V), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emblem0000N/A
(MJN.V)0000N/A

Valuation & Earnings

This table compares Emblem and (MJN.V)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71 million43.02C$-24,806,020.00($0.19)-9.89
(MJN.V)N/AN/AN/AN/AN/A

(MJN.V) has lower revenue, but higher earnings than Emblem.

Dividends

Emblem pays an annual dividend of $0.46 per share and has a dividend yield of 24.5%. (MJN.V) pays an annual dividend of C$1.65 per share and has a dividend yield of 13.6%. Emblem pays out -242.1% of its earnings in the form of a dividend.

Profitability

This table compares Emblem and (MJN.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmblemN/AN/AN/A
(MJN.V)N/AN/AN/A

Summary

Emblem beats (MJN.V) on 3 of the 3 factors compared between the two stocks.


Emblem Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
WEED
Canopy Growth
1.1$32.49+5.9%C$13.15 billionC$506.12 million-5.05
Leaf Mobile logo
LEAF
Leaf Mobile
1.2$0.36+2.8%C$2.47 billionC$19.24 million-59.17Gap Down
OrganiGram logo
OGI
OrganiGram
1.2$2.99+9.4%C$975.22 millionC$72.40 million-2.62Earnings Announcement
ICC
ICC Labs
0.5$1.62+6.2%C$228.24 millionC$533,684.0095.29Gap Down
CMED
(CMED.TO)
0.6N/AN/AC$0.00N/A0.00
MJN
(MJN.V)
0.5$12.15+1.9%C$0.00N/A0.00
SL
(SL)
0.6N/AN/AC$0.00N/A0.00High Trading Volume
Gap Up
BE
Beleave
0.6N/AN/AC$0.00N/A0.00High Trading Volume
BE
Beleave
0.6N/AN/A$0.00N/A0.00High Trading Volume
BLO
Cannabix Technologies
0.5N/AN/AC$0.00N/A0.00News Coverage
Gap Up
MGW
Maple Leaf Green World
0.6$0.79+88.6%C$0.00N/A0.00Gap Down
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.